Quellen

Quellen medizinischer Inhalte

R. van Vollenhoven, “Treat-to-target in rheumatoid arthritis — are we there yet?,”
Nat. Rev. Rheumatol., vol. 15, no. 3, pp. 180–186, Mar. 2019.
F. Salaffi et al., “Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis:
comparison with the conventional management approach,” 2016.
P. van Riel et al., “Improving inflammatory arthritis management through tighter monitoring of
patients and the use of innovative electronic tools,” RMD Open, vol. 2, no. 2, p. e000302, Nov. 2016.
L. G. Schipper, L. T. C. van Hulst, R. Grol, P. L. C. M. van Riel, M. E. J. L. Hulscher, and J. Fransen,
“Meta-analysis of tight control strategies in rheumatoid arthritis: Protocolized treatment has
additional value with respect to the clinical outcome,” Rheumatology, vol. 49, no. 11, pp. 2154–2164, 2010.
N. H. Martin et al., “Does intensive management improve remission rates in patients with
intermediate rheumatoid arthritis? (the TITRATE trial): Study protocol for a randomised controlled trial,”
Trials, vol. 18, no. 1, pp. 1–12, Dec. 2017.
C. Grigor et al., “Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study):
a single-blind randomised controlled trial,” Lancet, vol. 364, no. 9430, pp. 263–269, Jul. 2004.
E. Tanaka et al., “Efficient management of rheumatoid arthritis significantly reduces long-term
functional disability,” Ann. Rheum. Dis., vol. 67, no. 8, pp. 1153–1158, Aug. 2008.
S. M. M. Verstappen et al., “Intensive treatment with methotrexate in early rheumatoid arthritis:
Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis
(CAMERA, an open-label strategy trial),” Ann. Rheum. Dis., vol. 66, no. 11, pp. 1443–1449, 2007.
M. Vermeer et al., “Implementation of a treat-to-target strategy in very early rheumatoid arthritis:
Results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study,”
Arthritis Rheum., vol. 63, no. 10, pp. 2865–2872, Oct. 2011.
S. Ramiro et al., “Is treat-to-target really working in rheumatoid arthritis? a longitudinal
analysis of a cohort of patients treated in daily practice (RA BIODAM),”
Ann. Rheum. Dis., vol. 79, no. 4, pp. 453–459, Apr. 2020.
J. S. Smolen et al., “Treating rheumatoid arthritis to target:
2014 update of the recommendations of an international task force.”
B. Combe et al., “2016 update of the EULAR recommendations for the management of early arthritis,”
Ann Rheum Dis, vol. 76, pp. 948–959, 2017.
J. A. Singh et al., “2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis,”
Arthritis Rheumatol., vol. 68, no. 1, pp. 1–26, Jan. 2016.
M. Schneider et al., “Management of early rheumatoid arthritis: Interdisciplinary guideline,”
Zeitschrift fur Rheumatologie, vol. 79, no. 1. Springer Medizin, p. 24, 01-Jun-2020.
D. Wendling et al., “Recommendations of the French Society for Rheumatology (SFR)
on the everyday management of patients with spondyloarthritis,” Jt. Bone Spine, vol. 81, no. 1, pp. 6–14, 2014.
K. Albrecht et al., “German guidelines for the sequential medical treatment of rheumatoid arthritis with
traditional and biologic disease-modifying antirheumatic drugs,” Rheumatol. Int., vol. 34, no. 1, pp. 1–9, Jan. 2014.
V. P. Bykerk et al., “Canadian Rheumatology Association recommendations for pharmacological management
of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs,”
J. Rheumatol., vol. 39, no. 8, pp. 1559–1582, Aug. 2012.
“Rheumatoid arthritis in adults: management NICE guideline,” 2018.
C. Brettschneider, D. Lühmann, and H. Raspe, “Informative value of Patient Reported Outcomes (PRO)
in Health Technology Assessment (HTA).,” GMS Health Technol. Assess., vol. 7, p. Doc01, Feb. 2011.
J. Hendrikx, J. Fransen, and P. L. C M van Riel, “Monitoring rheumatoid arthritis using an algorithm
based on patient-reported outcome measures: a first step towards personalised healthcare,”
RMD Open, vol. 1, p. 114, 2015.
P. van Riel et al., “Improving inflammatory arthritis management through tighter monitoring of patients
and the use of innovative electronic tools,” RMD Open, vol. 2, no. 2, p. e000302, Nov. 2016.
B. Fautrel et al., “Call for action: how to improve use of patient-reported outcomes to
guide clinical decision making in rheumatoid arthritis.,” Rheumatol. Int., vol. 38, no. 6, pp. 935–947, 2018.
J. Hendrikx, M. J. de Jonge, J. Fransen, W. Kievit, and P. L. van Riel, “Systematic review of
patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis.,”
RMD open, vol. 2, no. 2, p. e000202, 2016.
A. Blanchais, J. M. Berthelot, A. M. Fontenoy, B. le Goff, and Y. Maugars, “Weekly home self-assessment of
RAPID-4/3 scores in rheumatoid arthritis: A 6-month study in 26 patients,”
Jt. Bone Spine, vol. 77, no. 6, pp. 582–587, 2010.
U. A. Walker et al., “Disease activity dynamics in rheumatoid arthritis:
patients’ self-assessment of disease activity via WebApp,” Rheumatology, no. 56, pp. 1707–1712, 2017.
M. Bossert, C. Prati, C. Vidal, S. Bongain, É. Toussirot, and D. Wendling, “Evaluation of self-report
questionnaires for assessing rheumatoid arthritis activity: A cross-sectional study of
RAPID3 and RADAI5 and flare detection in 200 patients,” Jt. Bone Spine, vol. 79, no. 1, pp. 57–62, Jan. 2012.
B. Rintelen, J. Sautner, P. Haindl, H. Mai, H. P. Brezinschek, and B. F. Leeb, “Remission in rheumatoid arthritis:
A comparison of the 2 newly proposed ACR/EULAR remission criteria with the rheumatoid arthritis disease
activity index-5, a patient self-report disease activity index,” J. Rheumatol., vol. 40, no. 4, pp. 394–400, Apr. 2013.
M. Krusche, N. Ruffer, M. Grahammer, and J. Knitza, “Mobile apps and their usage in rheumatology,”
Z. Rheumatol., vol. 79, no. 6, 2020.
M. Krusche et al., “Acceptance, Usage, and Barriers of Electronic Patient-Reported Outcomes
Among German Rheumatologists: Survey Study,” JMIR mHealth uHealth, vol. 8, no. 7, 2020.
J. Knitza et al., “Mobile Health Usage, Preferences, Barriers, and eHealth Literacy in Rheumatology:
Patient Survey Study,” JMIR mHealth uHealth, vol. 8, no. 8, p. e19661, Aug. 2020.
Y. El Miedany et al., “Toward electronic health recording: Evaluation of electronic patient-reported outcome
measures system for remote monitoring of early rheumatoid arthritis,”
J. Rheumatol., vol. 43, no. 12, pp. 2106–2112, 2016.
J. G. Richter et al., “Self-assessments of patients via Tablet PC in routine patient care:
Comparison with standardised paper questionnaires,” Ann. Rheum. Dis., vol. 67, no. 12, pp. 1739–1741, Dec. 2008.
A. de Thurah et al., “Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis:
Results of a Randomized Controlled Trial,” Arthritis Care Res. (Hoboken)., vol. 70, no. 3, pp. 353–360, Mar. 2018.
R. Grainger et al., “Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity:
A Review of Apps for Best Practice and Quality.”
H. Radner, J. S. Smolen, and D. Aletaha, “Remission in rheumatoid arthritis: benefit over low disease activity in
patient-reported outcomes and costs,” Arthritis Res. Ther., vol. 16, no. 1, p. R56, Feb. 2014.

Quellen medizinischer Informationen

Aktuelle Therapieüberwachungsbögen der Deutsche Gesellschaft für Rheumatologie (DGRh): https://dgrh.de/Start/Versorgung/Therapieinformationen/Therapieinformationsb%C3%B6gen.html

Medizinische Zweckbestimmung

Funktionsumfang

Nutzungsausschluss

Kompatibilität

Interoperabilität

Quellen

Quellen medizinischer Inhalte

Quellen medizinischer Informationen

Qualitätssiegel

CE-Zertifiziertes digitales Medizinprodukt

Teilnehmer Allianz für Cybersicherheit

Gewinner Pitching Event
3rd Digital Rheumatology Day

Top 2 Beyond Rheum 2022
by EIT Health & Novartis Spain

Top 5 DiGA-Pitch-Battle der DGIM 2022

Top 8 Wittener Preis für Gesundheitsvisionäre 2021

Finalist EIT Health Headstart 2019

Top 10 Startupbootcamp Digital Health Cohort 2018

ABATON GmbH

E-Mail

WEBSITE

Medizinische Zweckbestimmung

Funktionsumfang

Nutzungsausschluss

Kompatibilität

Interoperabilität

Quellen

Quellen medizinischer Inhalte

Quellen medizinischer Informationen

Qualitätssiegel

CE-Zertifiziertes digitales Medizinprodukt

Teilnehmer Allianz für Cybersicherheit

Gewinner Pitching Event 3rd Digital Rheumatology Day

Top 2 Beyond Rheum 2022by EIT Health & Novartis Spain

Top 5 DiGA-Pitch-Battle der DGIM 2022

Top 8 Wittener Preis für Gesundheitsvisionäre 2021

Finalist EIT Health Headstart 2019

Top 10 Startupbootcamp Digital Health Cohort 2018

ABATON GmbH

E-Mail

WEBSITE

Gewinner Pitching Event
3rd Digital Rheumatology Day

Top 2 Beyond Rheum 2022
by EIT Health & Novartis Spain